ROSSARI

- Rossari Biotech Limited will not participate in Nirmal Bang's Semi-Annual Investor Conference. - The event was scheduled for Monday, August 10, 2026.

- Concall Schedule - Concall Date: August 10, 2026 - Concall Time: 02:00 PM (IST) - Conference: Nirmal Bang's Semi-Annual Investor Conference - Meeting Type: One-on-One & Group - Location: Mumbai

- Consolidated revenue for Q1 FY27 stood at ₹697.2 crore, marking a 28% YoY growth, the highest ever quarterly revenue. - EBITDA reached ₹80.6 crore, an 18.7% YoY growth, also the highest ever quarterly EBITDA. However, EBITDA margins contracted to 11.6% from 12.5% in the corresponding quarter last year. - Net Profit (PAT) grew by 4.5% YoY to ₹35.1 crore. - The company aims to stabilize EBITDA margins around 15% in 2-3 years through product mix optimization, exiting low-margin B2C businesses (expected to release 2-3% EBITDA margin), and improved capacity utilization. - Maintained FY27 top-line growth guidance of ~15% YoY, with FY28 expected to be better due to increased EO availability. - Net debt reduced to ₹248 crore from ₹280 crore in March. - New pharma business products started contributing, with a revenue potential of ₹30-50 crore for FY27, aiming for ₹70-75 crore for the year. - Progress on Saudi Arabia greenfield facility (1.5 years to production post-announcement) and new blending plant in Thailand (currently ₹2-3 crore revenue) as future growth drivers.

- The 17th Annual General Meeting (AGM) of Rossari Biotech Limited was held on July 20, 2026. - All resolutions, including the adoption of financial statements for FY2025-26, were passed with requisite majority. - A dividend of ₹0.50 (25%) per Equity Share was declared for the Financial Year ended March 31, 2026. - Appointments and re-appointments of directors were also approved.

- Audio recording of the Earnings Conference Call for Q1 FY27 held on July 20, 2026, is available on the company's website at www.rossari.com/announcement-2/ under the 'Investor Call' section.

- Clarification regarding Rossari Employee Stock Option Plan 2019. - Number of options granted corrected from 4,000 to 5,000.

- Consolidated Revenue ₹697.2Cr vs ₹543.7Cr (▲28% YoY) - EBITDA ₹80.6Cr vs ₹67.9Cr (▲19% YoY) - PAT ₹35.1Cr vs ₹33.6Cr (▲4% YoY) - EBITDA Margin 11.6% vs 12.5% (▼90bps)

- Board approved Unaudited Financial Results for Q1 FY27 (June 30, 2026). - Granted 4000 Stock Options under ESOP 2019 (exercise price Rs. 531). - Allotted 2500 equity shares from exercised ESOPs (exercise price Rs. 425). - Approved internal transfer of subsidiary for approx. ₹24 Cr to streamline overseas operations.

- Board approved Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026. - Approved grant of 4000 Stock Options under ESOP 2019 with an exercise price of ₹531 per option. - Approved allotment of 2500 Equity Shares at ₹425 per share, resulting from the exercise of options under ESOP 2019. - Approved transfer of 100% shareholding of Rossari International Limited Company (RILC) to Rossari (Singapore) Pte. Ltd. as part of an internal restructuring valued at ~₹24 Crores.

- The Board approved the unaudited financial results (standalone and consolidated) for the quarter ended June 30, 2026. - Grant of 4000 Stock Options under ESOP 2019 at an exercise price of ₹531 per option was approved. - Allotment of 2500 Equity Shares under ESOP 2019 was also approved. - The transfer of 100% shareholding of Rossari International Limited Company to Rossari (Singapore) Pte. Ltd. (~₹24 Cr) was approved as part of an internal restructuring.

- Board of Directors approved Unaudited Financial Results for the quarter ended June 30, 2026. - Approved the grant of 4000 Stock Options under ESOP 2019 (exercise price Rs. 531) and the allotment of 2500 Equity Shares under ESOP 2019. - Approved the transfer of 100% shareholding of Rossari International Limited Company to Rossari (Singapore) Pte. Ltd. for approximately ₹24 Crores as part of an internal group restructuring.

New Filing detected. See link for details.

- The 17th Annual General Meeting (AGM) of Rossari Biotech Limited will be held on Monday, July 20, 2026, at 11:00 A.M. (IST) via Video Conferencing (VC)/Other Audio-Visual Means (OAVM). - The Integrated Annual Report for FY 2025-26 is available on the company's website and stock exchange websites. - The record date for dividend entitlement for FY 2025-26 is Friday, July 10, 2026. - Remote E-voting will commence on Friday, July 17, 2026, and end on Sunday, July 19, 2026. - Dividend payout will occur within 10 working days from the conclusion of the 17th AGM.

- Rossari Biotech Limited filed its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26. This report details the company's commitment to environmental stewardship, social responsibility, and governance excellence. Key initiatives cover energy, water, and waste management. Turnover for FY26 was ₹17,521 million.

- 17th AGM on July 20, 2026, via VC/OAVM. - Agenda: Adopt FY26 financials, declare ₹0.50 (25%) dividend per equity share, appoint/re-appoint directors, ratify cost auditors, and approve related party transaction (₹10,290 Cr).

- Rossari Biotech's subsidiary, Unistar Thai Co., has established a new blending facility in Thailand with an installed capacity of 5000 MTPA. - This facility is strategically positioned to serve as a regional technical hub, addressing the Southeast Asian market and enhancing manufacturing capabilities and supply chain resilience.

- Rossari Biotech Limited announced the closure of its trading window from July 01, 2026, until 48 hours after the announcement of unaudited financial results for the quarter ending June 30, 2026.

- The 17th Annual General Meeting (AGM) will be held on July 20, 2026, at 11:00 A.M. (IST) via video conference. - The Record Date for determining entitlement for dividend (if declared for FY 2025-26) is July 10, 2026. - Dividend payment, if declared, will be made within 10 working days from the conclusion of the AGM. - The cut-off date for remote e-voting is July 13, 2026.

- 17th Annual General Meeting (AGM) to be held on Monday, July 20, 2026, at 11:00 A.M. (IST) via Video Conference. - Record Date for payment of dividend for FY 2025-26 is Friday, July 10, 2026. - Cut-off date for remote e-voting is Monday, July 13, 2026.

- Concall Schedule - Concall Date: June 12, 2026 - Concall Time: 12:00 PM (IST)

- Rossari Biotech Limited has been served with a petition on June 04, 2026, challenging the Arbitration Award dated January 21, 2026. - The petition was filed by sellers of Unitop Chemicals Private Limited, a material unlisted subsidiary, under Section 34 of the Arbitration and Conciliation Act, 1996. - This relates to an arbitration proceeding concerning the share purchase agreement for Unitop Chemicals.